Marcelo F. Di Carli, MD, FACC
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Marcelo F. Di Carli, MD, FACC sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Marcelo F. Di Carli, MD, FACC: 4 sponsored US clinical trials, none currently recruiting.
Marcelo F. Di Carli, MD, FACC sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cardiovascular Disease, with 1 trials.
Upper-quartile sponsor footprint
Marcelo F. Di Carli, MD, FACC sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
MIcrovascular dysfuNction In Moderate-severe Psoriasis
NCT04271540
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
NCT02546388
FET-PET for Evaluation of Response of Recurrent GBM to Avastin
NCT01756352
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
NCT01240161
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
How the Marcelo F. Di Carli, MD, FACC archive is shaped
4 indexed studies, none listed as recruiting (0% open); 4 completed (100%).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Cardiovascular Disease (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Marcelo F. Di Carli, MD, FACC: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Marcelo F. Di Carli, MD, FACC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Marcelo F. Di Carli, MD, FACC page
4 registered trials is a research-attention snapshot, not an endorsement of Marcelo F. Di Carli, MD, FACC or any single study.
- None of Marcelo F. Di Carli, MD, FACC's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Cardiovascular Disease is the condition Marcelo F. Di Carli, MD, FACC studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cardiovascular Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Marcelo F. Di Carli, MD, FACC pipeline card: 4 registered trials from official public datasets.Report a data error.